PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9576639-1	1998	INTRODUCTION: This study evaluates the activity of SDZ ENA 713, a centrally-selective acetylcholinesterase (AChE) inhibitor, in the cerebral spinal fluid (CSF) of patients with Alzheimer"s disease (AD), and its relationship to central and peripheral pharmacokinetic parameters.	Sulfadiazine	51-54	acetylcholinesterase (Cartwright blood group)	Homo sapiens	108-112	
9576639-7	1998	CONCLUSION: Rapid, sustained, dose-dependent inhibition of CSF AChE suggests that SDZ ENA 713 has therapeutic potential in AD patients.	Sulfadiazine	82-85	acetylcholinesterase (Cartwright blood group)	Homo sapiens	63-67	
1776750-0	1991	Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.	Sulfadiazine	53-56	acetylcholinesterase (Cartwright blood group)	Homo sapiens	88-108